Non-Obstructive Coronary Artery Disease
Conditions
Keywords
Non-Obstructive Coronary Artery Disease, Coronary Angiography
Brief summary
The study will estimate the current status of participants with non-obstructive coronary artery disease confirmed via coronary angiography.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Participants who had typical or atypical angina symptom before Coronary Angiography examination * Underwent CAG between 01 Jan 2013 and 31 Dec 2015 * Other protocol defined inclusion criteria could apply
Exclusion criteria
* Participant with history of percutaneous coronary intervention or coronary artery bypass surgery * Participant with history of myocardial infarction * Participant with history of cardiac transplant or valve surgery * Presenting with Acute myocardial infarction for coronary angiography * CAG showed myocardial bridge and coronary stenosis greater than or equal to 50 percent during systole period * Incomplete or missing data in CAG report * Other protocol defined
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Participants with Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Angina Symptoms | Up to 10 months | — |
| Percentage of Participants With Pathologic Echocardiography Results | Up to 10 Months | — |
| Ventricular Wall thickness in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months | Mean left ventricular posterior wall thickness (LVPW), interventricular septum (IVS) thickness, other ventricular wall thickness will be assessed for the participants with obstructive and non-obstructive CAD. |
| Left Ventricular End-Diastolic Volume (LVEDV) in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months | — |
| Left Ventricular End Diastolic Diameter (LVEDD) in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months | — |
| Ventricular Wall Motion in Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months | — |
| Percentage of Participants With Combined Cardiovascular Risk Factors | Up to 10 Months | Combined cardiovascular risk factors include: body mass index, smoking habit, hypertension, hyperlipidemia diabetes mellitus, lack of exercise, alcohol intake and family history of early onset cardiovascular disease. Percentage of participants with combined cardiovascular risk factors will be reported. |
| Left Ventricular Ejection Fraction (LVEF) in Participants with Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months | — |
| Percentage of Participants Receiving Anti-ischemic Drugs | Up to 10 Months | — |
| Percentage of Participants with Myocardial Event Prevention | Up to 10 Months | Percentage of participants achieving event prevention by antiplatelet agent, anticoagulants, β-blockers, Angiotensin converting enzyme inhibitor (ACEI), Angiotensin receptor blocker (ARB), statin, aldosterone antagonist will be reported. |
| Percentage of Participants With Obstructive and Non-Obstructive Coronary Artery Disease (CAD) Segregated by Age Groups, Genders, Races and Provinces | Up to 10 Months | — |
| Correlation Coefficient Between Participants With Non-obstructive CAD confirmed by CAG and Clinical Characteristics | Up to 10 Months | Correlation coefficient between the participants with non-obstructive CAD and different clinical characteristics like demographic characteristics, combined cardiovascular risk factors and angina symptoms will be assessed using logistic regression analysis. |
| Ratio of Early Trans-Mitral Flow (E) and Late Trans-Mitral Flow by Atrial Contraction (A) in Participants with Obstructive and Non-Obstructive Coronary Artery Disease (CAD) | Up to 10 Months | — |
Countries
Germany